Giotrif, known generically as afatinib, is a prescription medication used in the treatment of certain types of non-small cell lung cancer (NSCLC). It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking the action of a specific protein (epidermal growth factor receptor or EGFR) that signals cancer cells to multiply. This action helps in slowing down or stopping the growth of cancer cells. Giotrif is specifically used for NSCLC that has specific genetic mutations, and its use is often determined after testing the cancer for these mutations. It is administered orally in tablet form. As with any cancer therapy, it may come with a range of side effects, and its use is closely monitored by healthcare professionals.